Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
Jun 15 2010
Lasmiditan (COL-144; LY573144) is a novel, highly selective and potent agonist at 5-HT1F receptors that lacks vasoconstrictor activity. Preclinical and early clinical experiments predict acute ntimigraine efficacy of COL-144 that is mediated through a non-vascular, primarily neural, mechanism.
Link available:
http://cep.sagepub.com/content/30/10/1170.abstract
Source: Cephalalgia